Detailed explanation of whether Gilteritinib has been included in medical insurance and reimbursement policy

Gilitinib is an oral small molecule FLT3 inhibitor, mainly used to treat patients with relapsed or refractory acute myeloid leukemia (R/R AML) with FLT3 mutations. In China, giritinib has been launched, providing a new treatment option for high-risk patients. However, as of 2025, it has not yet been included in the national medical insurance system, so it may be difficult to purchase the drug directly in the hospital. If patients need to use this medicine, they usually need to obtain it through overseas channels to ensure that the source of the medicine is formal and reliable.

In the international market, giritinib can be divided into two categories: original drugs and generic drugs. The original drugs mainly include the European version and the Hong Kong version. Among them, the price of the Hong Kong version of giritinib is as high as about 100,000 yuan, which is a huge financial burden for ordinary patients. Therefore, if financial conditions permit, some patients may choose to purchase through formal overseas channels to meet their treatment needs.

In comparison, the prices of generic drugs listed overseas are more affordable. For example, the price of the Laos version of giritinib is only more than 1,000 to 2,000 yuan, which has obvious price advantages. Although the price is low, the ingredients of these generic drugs are basically the same as the original drugs, which can reduce the financial pressure on patients while ensuring the efficacy. Patients still need to confirm that the source of drugs is regular when choosing to ensure the safety and efficacy of the drugs.

Generally speaking, although giritinib is already on the market in China, it is not included in medical insurance. Patients need to purchase the drug through overseas channels or specific medical channels. For patients with limited economic conditions, generic drugs provide a feasible option, but they still need to follow the guidance of doctors during use and regularly monitor hematological indicators and therapeutic responses. At the same time, with the gradual improvement of medical insurance policies and the advancement of drug approval processes, the possibility of giritinib being included in medical insurance will increase in the future, providing a safe and accessible treatment option for more high-risk AML patients.

Reference materials:https://www.drugs.com/